Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New insights into the treatment of obesity.
Blüher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, Pietiläinen KH, Schnell O, Tonchevska E, Wilding JPH. Blüher M, et al. Among authors: wilding jph. Diabetes Obes Metab. 2023 Aug;25(8):2058-2072. doi: 10.1111/dom.15077. Epub 2023 May 5. Diabetes Obes Metab. 2023. PMID: 37055715 Review.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I. Cahn A, et al. Among authors: wilding jph. Diabetes Obes Metab. 2021 Jan;23(1):29-38. doi: 10.1111/dom.14179. Epub 2020 Sep 22. Diabetes Obes Metab. 2021. PMID: 32844557 Clinical Trial.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Sargeant JA, King JA, Yates T, Redman EL, Bodicoat DH, Chatterjee S, Edwardson CL, Gray LJ, Poulin B, Waheed G, Waller HL, Webb DR, Willis SA, Wilding JPH, Khunti K, Stensel DJ, Davies MJ. Sargeant JA, et al. Among authors: wilding jph. Diabetes Obes Metab. 2022 Aug;24(8):1509-1521. doi: 10.1111/dom.14721. Epub 2022 May 13. Diabetes Obes Metab. 2022. PMID: 35441435 Free PMC article. Clinical Trial.
278 results